98
Diagnostic preparations
exametazime
gadobenate dimeglumine
gadobutrol
gadodiamide
gadopentetate
gadoteric acid
gadoteridol
gadoxetic acid
iodixanol
iohexol
iomeprol
iopamidol
iopromide
ioversol
meglumine iothalamate
meglumine iotroxate
metyrapone
tetrofosmin
thyrotrophin alfa
Combination products
G
astrografin
,M
d
-76,M
d
-
gastroview
:sodium
diatrizoate 10% and meglumine diatrizoate
66%.
U
rografin
30%: sodium amidotrizoate 40
mg/mL and meglumine amidotrizoate 260
mg/mL.
U
rografin
76%: sodium amidotrizoate 100
mg/mL and meglumine amidotrizoate 660
mg/mL.
exametazime
Ceretec
Pregnancy risk category C
Use in sport: Permitted
Available form
Solution for injection:
0.5 mg/0.5 mL
Indications & dosages
➤
Scintigraphic identification of seizure foci in
individualswithtemporal lobeepilepsy—
Adults:
350–500 MBq IV. Dynamic imaging
may be performed between 0 and 10
minutes following injection. Static imaging
may be performed from 15 minutes up to 6
hours after injection.
Action
Diagnostic radiopharmaceutical preparation
that assists detection of altered perfusion in
areas of the cerebrum.
Route Onset
Peak
Duration
IV
Immediate Unknown 6 hrs
Adverse reactions
CV:
transient blood pressure elevation,
vascular spasm.
Skin:
rash, urticaria.
Other:
facial or generalised oedema, fever,
mild hypersensitivity.
Interactions
None reported.
Contraindications
Contraindicated in individuals with known
hypersensitivity to the preparation.
care considerations
•
Alert:
Radioactive drug—drug must be
handled with care and appropriate safety
measures should be used to minimise
radiation exposure to the individual and to
staff.
• Reconstituted agent must be used within
30 minutes.
• Monitor blood pressure following
procedure.
• Due to potential for bladder radiation,
encourage person to follow adequate
hydration and to void straight after the
procedure, then regularly thereafter.
• Women who are breastfeeding should
discontinue breastfeeding for at least
